Global Artificial Intelligence in Omics Studies Market Overview
As per MRFR analysis, the Artificial Intelligence in Omics Studies Market Size was estimated at 4.44 (USD Billion) in 2022.
The Artificial Intelligence in Omics Studies Market Industry is expected to grow from 5.45 (USD Billion) in 2023 to and USD 6.69 billion in 2024 and 34.5 (USD Billion) by 2032. The Artificial Intelligence in Omics Studies Market CAGR (growth rate) is expected to be around 22.76% during the forecast period (2023 - 2032).
Key Artificial Intelligence in Omics Studies Market Trends Highlighted
Omics research is currently undergoing a revolution due to Artificial intelligence, which is providing transformative capabilities in data analytics as well as biomarker discovery and personalized medicine. According to the forecast provided by the Market Research Future (MRFR), the AI in Omics Studies Market is expected to grow at a CAGR of 22.76% over the period of 2023-2032, with an estimated value of USD 34.5 billion by 2032.
The increase in the totals and intricacy of Omics data merged with precision medicine demand has facilitated the integration of AI into Omics studies. There are several main factors that enable the market to include such as AI’s capacity to accelerate data processes and analysis, improve forecast modeling, and create individualized healthcare plans.
Some trends in this space indicate the emergence of deep learning, machine learning, and cloud computing. These techniques have made it possible for AI algorithms to handle huge quantities of Omics data by providing capabilities for efficiently and accurately handling large volumes of Omics data using AI algorithms. In addition, interpretable AI has been stressed to foster AI models’ transparency and accountability towards gaining trust within the medical sector.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Omics Studies Market Drivers
-
Key Market Drivers for the Global Artificial Intelligence in Omics
Increasing Adoption of AI in Healthcare and Life Sciences Research
Healthcare and life sciences are changing fast due to artificial intelligence (AI). At present, AI-supported instruments are being used to make predictions based on a volume of data and identify patterns that can enhance patient care as well as speed up drug discovery. This is expected to be the case in the future thus driving Artificial Intelligence in Omics Studies Market Industry growth.
-
Rising Need for Customized Healthcare
In other words, personalized medicine requires health systems to take into account individual differences based on genetic variation, environmental factors, and lifestyle. Today, big data is being analyzed by artificial intelligence (AI) for the identification of personalized patterns. Accordingly, these data could be used in the creation of custom treatments and interventions that have a higher chance of success.
-
Government Initiatives and Funding
Governments all over the world have started acknowledging the impact of AI on healthcare delivery systems as well as life science. They have increased funding for research and development projects in this area. The favorable environment being created will continue boosting Artificial Intelligence in Omics Studies Market Industry growth.
Artificial Intelligence in Omics Studies Market Segment Insights
Artificial Intelligence in Omics Studies Type of Omics Studies Insights
The Type of Omics Studies segment plays a crucial role in shaping the Artificial Intelligence in Omics Studies Market. This market is divided into five major sub-segments: genomics, transcriptomics, proteomics, metabolomics and epigenomics. That year, genomics as a whole-genome information research method accounted for the largest part of the market at USD 1.85 billion due to the ascendency of Next Generation Sequencing (NGS) technologies and increasing numbers of genome sequencing projects; in addition, further growth has been achieved through increased need for RNA sequencing services that support biomarker discovery and drug development activities.
Transcriptomics is forecasted to grow at a CAGR of 20.5% by 2032, reaching USD 8.2 billion towards the end of the forecast period. Proteomics, on the other hand, will register a CAGR of 21.5% during this period, with its value hitting USD 7.5 billion by 2032, and it’s expected that this increase will be driven by increased use of proteomic techniques in disease diagnosis, identification of biomarkers and drug discovery projects’ purposes. Metabolomics segment, which analyzes small molecules called metabolites, is another fast-growing one projected to reach $4.2bn by 2032, showing a CAGR of 23.5%.
The reason behind Metabolonics’ growth is its use in metabolic pathway analysis, marker identification and individualized therapy; nevertheless, Epigenetics or chemical modification study on specific genes on DNA stands a smaller field with much hope ahead, too. Epigenetic treatment potentiality, including recognition among various disease initiation mechanisms, accounts for approximately estimated growth rate from 2015 up to 2032, amounting to $USD2.8bn at about 25.5%. To sum up, the Type of Omics Studies gives profitable opportunities for companies operating within the Artificial Intelligence in Omics Studies Market.
With more applications being discovered every day for AI in omic studies, there is little doubt that adoption rates will continue rising exponentially.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Omics Studies Application Insights
Omics Studies, Disease Diagnosis, Drug Discovery, Personalized Medicine, Biomarker Discovery and Toxicology Studies are the five categories to which the Artificial Intelligence in Omics Studies Market Application is classified. In 2023, the highest demand for early and accurate disease diagnosis will mean that Disease Diagnosis takes the largest market share. On the other hand, personalized therapies have led to an upsurge in the number of drugs being produced; hence drug discovery sector will experience the highest growth rate among others.
However, it is worth noting how important personalized medicine can be as treatment plans may be developed based on individual genetic profiles. The biomarkers discovery is a critical step towards finding disease-specific markers used in diagnosis and prognosis. Conversely, AI aids toxicological studies by evaluating chemicals for toxicity and safety concerns.
Artificial Intelligence in Omics Studies AI Technique Insights
The Global Market For Artificial Intelligence In Omics Studies Is Categorized Based On AI Techniques Into Machine Learning, Deep Learning, Natural Language Processing, Computer Vision And Data Mining. Out of these, the Machine Learning segment is expected to have the largest market share at about 40% by 2024 and reach a valuation of approximately USD 13.6 billion by 2032, growing at a CAGR of 21.5% during the forecast period; it owes its success to growing adoption of machine learning algorithms in omics studies for data analysis and pattern recognition.
Another notable segment is Natural Language Processing with an anticipated growth rate of 24.2% over the forecast period due to its ability to handle large volumes of unstructured text data such as scientific literature and patient records. The Computer Vision sector will also record significant progress as image analysis techniques are increasingly used in omics studies for disease diagnosis and drug discovery.
Artificial Intelligence in Omics Studies Regional Insights
The North American area is one of the prime contributors, and the market is expected to reach USD 20.4 Billion by 2032, growing at a CAGR of 22.76% from 2024 to 2032. This can be attributed to reasons like increased investment in healthcare IT, rise in demand for personalized medicine and AI technologies used for data analysis and interpretation, among others. The European market will grow significantly due to its well-established healthcare system and high research spending.
On the other hand, South America and MEA would grow at a steady pace because there are more medical facilities available and more skilled professionals on board. APAC has recently come up rapidly due to the faster-expanding healthcare sector and increasing governmental emphasis on AI technology.
The Omics Studies Artificial Intelligence (AI) market is expected to achieve significant growth in the years ahead with the North American region seen as a key part of this. The regional market size is projected to reach USD 20.4 billion by 2032, growing at a CAGR of 22.76% from 2024 to 2032, thus boosting demand for AI in genomics and proteomics applications. This development comes as a result of several drivers, including enhanced healthcare IT spending, an increasing need for personalized medicine, and the application of AI technologies in data analysis and interpretation. Europe is also likely to be instrumental in the expansion due to its advanced health infrastructure and heavy R budgets.
There are immense growth opportunities present within APAC because of its speedy development medical care industry together with the upsurge government’s involvement in AI. South America and MEA are anticipated to witness steady growth, driven by expanding healthcare facilities and the availability of skilled professionals as well.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Artificial Intelligence in Omics Studies Market Key Players And Competitive Insights
Artificial Intelligence in Omics Studies Market has its major players in the industry making continuous investments in R&D to enhance their offerings and gain a competitive advantage. Leading the market for Artificial Intelligence in Omics Studies are companies such as IBM, Google, Microsoft, Amazon and NVIDIA, who look forward to formulating new approaches through which researchers would analyze large volumes of data that is complex. This is possible by building partnerships with other organizations or even going into new markets. As a case in point, IBM has taken up a partnership with the University of Oxford to establish AI that is brand new, and that can be used to analyze genetic information and thus help scientists identify any genetic abnormalities that may lead to diseases.
Moreover, the growth of Artificial Intelligence (AI) in the Omics Studies Market is prompted further by the escalating adoption of artificial intelligence (AI) and machine learning technologies (ML) in the healthcare sector. The use of AI and ML could aid in the automation of processes leading to better precision as well as providing insights to enable better decisions by researchers.
For instance, AI can detect patterns within genetic data that might be associated with diseases. From this point forward, it can be used to construct diagnostic strategies for illness as well as prescription strategies. The availability of large and intricate datasets has also contributed to market expansion. The emergence of next-generation sequencing (NGS) technologies has made it possible to produce enormous quantities of information for studying the human genome. Therefore, such data are then scrutinized by AI or ML, which can detect patterns that signify diseases.
Another key player in Artificial Intelligence in Omics Studies Market is Illumina Inc., which is one of the leading providers of NGS instruments as well as reagents based kits for DNA sequencing, etc. The company also develops software employing artificial intelligence algorithms specifically designed for genomics interpretation.”Google partnership:” Additionally, Microsoft has joined hands with Illumina at developing novel artificial intelligence solutions in the health sector”. This company also invests largely in research and development so that it may improve on its capabilities by using AI like developing some new algorithms able to detect some specific genes associated with illnesses. In addition, Illumina is developing new AI tools for drug design and validation.
Key Companies in the Artificial Intelligence In Omics Studies Market Include:
- Pacific Biosciences of California, Inc.
- Myriad Genetics, Inc.
- BD (Becton, Dickinson and Company)
- BioRad Laboratories, Inc.
- Oxford Nanopore Technologies, PLC
- PerkinElmer, Inc.
- Agilent Technologies
- Sequenom, Inc.
- QIAGEN
- Illumina, Inc.
- Trimble Inc.
- Abbott Laboratories
- Thermo Fisher Scientific
- HoffmannLa Roche Ltd.
- Novogene Co., Ltd.
Artificial Intelligence in Omics Studies Market Industry Developments
During the next few years, it is expected to witness a significant increase in the Omics Studies Artificial Intelligence (AI) market owing to improvements in AI algorithms, increased use of omics technologies and the growing demand for personalized medicine. IBM, Thermo Fisher Scientific, Illumina, QIAGEN and Agilent Technologies are some of the players operating in this market.
The latest developments in this market include but are not limited to new AI-based omics analysis platforms such as IBM’s Watson for Genomics or Thermo Fisher’s Ion Torrent Genexus System, which enable researchers to perform much easier and accurate analyses on huge datasets of omics, hence improving biomarker discovery and drug development.
Moreover, market growth is also fueled by the increasing adoption of cloud-based omics analysis solutions, which provide researchers with scalable and cost-effective computational resources through cloud computing.
Artificial Intelligence in Omics Studies Market Segmentation
Artificial Intelligence In Omics Studies Market Type Outlook
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Epigenomics
Artificial Intelligence In Omics Studies Application Outlook
- Clinical Diagnostics
- Drug Discovery & Development
Artificial Intelligence In Omics Studies Technology Outlook
- Machine Learning
- Deep Learning
- Others
Artificial Intelligence in Omics Studies Offering Outlook
Artificial Intelligence In Omics Studies Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2022
|
4.44 (USD Billion)
|
|
Market Size 2023
|
5.45 (USD Billion)
|
|
Market Size 2032
|
34.5 (USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
22.76% (2023 - 2032)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2023 - 2032
|
|
Historical Data
|
2019 - 2023
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Pacific Biosciences of California, Inc., Myriad Genetics, Inc., BD (Becton, Dickinson and Company), BioRad Laboratories, Inc., Oxford Nanopore Technologies, PLC, PerkinElmer, Inc., Agilent Technologies, Sequenom, Inc., QIAGEN, Illumina, Inc., Trimble Inc., Abbott Laboratories, Thermo Fisher Scientific, F. HoffmannLa Roche Ltd., Novogene Co., Ltd.
|
|
Segments Covered
|
Type of Omics Studies, Application, AI Technique, Regional
|
|
Key Market Opportunities
|
Precision medicine Drug discovery Disease diagnosis Personalized treatments Population health management
|
|
Key Market Dynamics
|
Increasing adoption of AI in healthcare Rising demand for personalized medicine Growing volume of omics data Advancements in machine learning algorithms Increasing government support for AI research
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Frequently Asked Questions (FAQ) :
The Artificial Intelligence in Omics Studies market is expected to reach USD 8.32 billion by 2024, exhibiting a CAGR of 22.76% during the forecast period (2023-2032).
North America held the largest market share in 2022 and is expected to maintain its dominance throughout the forecast period. However, the Asia Pacific region is projected to witness the fastest growth, owing to the increasing adoption of AI technologies in healthcare and the rising prevalence of chronic diseases.
Key applications of Artificial Intelligence in Omics Studies include: Drug discovery and development medicine diagnosis and prognosis biomarkers discoveryPersonalized treatment planning.
Major competitors in the Artificial Intelligence in Omics Studies market include IBM, Google, Microsoft, Amazon Web Services, NVIDIA, Illumina, Thermo Fisher Scientific, Agilent Technologies, PerkinElmer and QIAGEN.
Key growth drivers of the Artificial Intelligence in Omics Studies market include increasing demand for personalized medicine, prevalence of chronic diseases, Technological advancements in AI and machine learning, and growing adoption of AI in healthcare Government initiatives to promote AI research.
Challenges faced by Artificial Intelligence in the Omics Studies market include a lack of skilled professionals, Data privacy and security concerns, Regulatory issues Cost of implementation Integration challenges.
Future trends in the Artificial Intelligence in Omics Studies market include Increasing adoption of AI in drug discovery, development of new AI algorithms and techniques, integration of AI with other technologies, such as blockchain and the Internet of Things, Growing focus on precision medicine and personalized treatment.
The COVID-19 pandemic has had a positive impact on the Artificial Intelligence in Omics Studies market, as it has accelerated the adoption of AI technologies in healthcare. AI has been used to develop new drugs and vaccines, track the spread of the virus, and provide personalized treatment plans for patients.
The regulatory landscape of the Artificial Intelligence in Omics Studies market is still evolving. However, there are a number of regulations that apply to the use of AI in healthcare, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union.
Key opportunities for growth in the Artificial Intelligence in Omics Studies market include the development of new AI algorithms and techniques, integration of AI with other technologies, such as blockchain and the Internet of Things, growing focus on precision medicine and personalized treatment expansion into new markets, such as developing countries.
